stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) Net income
Medpace Holdings, Inc.'s net income for fiscal 2025 was $451.1M, up 11.6% from $404.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $517.8M. Over the past ten years it has ranged from −$8.7M (fiscal 2015) to $451.1M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 10 consecutive fiscal years. Medpace Holdings, Inc. ranks 10th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $451.1M | 11.56% |
| FY2024 | $404.4M | 42.99% |
| FY2023 | $282.8M | 15.26% |
| FY2022 | $245.4M | 34.93% |
| FY2021 | $181.8M | 25.08% |
| FY2020 | $145.4M | 44.74% |
| FY2019 | $100.4M | 37.25% |
| FY2018 | $73.2M | 87.07% |
| FY2017 | $39.1M | 191.41% |
| FY2016 | $13.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $137.5M | 13.26% |
| Jun 2026 | $121.4M | (2.02%) |
| Mar 2026 | $123.9M | (8.33%) |
| Dec 2025 | $135.1M | 21.59% |
| 41 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| ILMN Illumina, Inc. compare | $895.0M |
| MEDP Medpace Holdings, Inc. | $517.8M |
| ICLR ICON PLC compare | $448.7M |
| QGEN QIAGEN N.V. compare | $409.3M |
| RVTY Revvity Inc. compare | $253.2M |
| CRL Charles River Laboratories International, Inc. compare | $42.6M |
| GH Guardant Health, Inc. compare | −$485.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on MEDP
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement